Timolol therapy in secondary angle-closure glaucoma post penetrating keratoplasty.
Timolol maleate (o.25% or 0.5% twice a day) was used in 13 eyes of 13 patients with secondary angle-closure glaucoma post penetrating keratoplasty uncontrolled on miotics, carbonic anhydrase inhibitors, or both. When added to each patient's current regimen, tomolol controlled 9 of the 13 eyes that no longer required cyclocryotherapy, and it was well tolerated locally and systemically. Its ocular hypotensive effect appears to supplement miotics and carbonic anhydrase inhibitors.
D002257:Carbonic Anhydrase Inhibitors / Q000627:therapeutic use; D016039:Corneal Transplantation; D004359:Drug Therapy, Combination; D005260:Female; D005901:Glaucoma / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008916:Miotics / Q000627:therapeutic use; D011183:Postoperative Complications; D011412:Propanolamines / Q000627:therapeutic use*; D013999:Timolol / Q000494:pharmacology / Q000627:therapeutic use*; D014184:Transplantation, Homologous
D002257:Carbonic Anhydrase Inhibitors; D008916:Miotics; D011412:Propanolamines; D013999:Timolol